Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities

Circulation

Volumn 101, Issue 21, 2000, Pages 2510-2517

  Aviram, Michael ^a,b   Hardak, Emiliya ^a   Vaya, Jacob ^c   Mahmood, Saeed ^c   Milo, Simcha ^b   Hoffman, Aaron ^b   Billicke, Scott ^d   Draganov, Dragomir ^d   Rosenblat, Mira ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Arteries; Atherosclerosis; Carotid arteries; Cholesterol; Fatty acids; Lesion; Lipids

Indexed keywords

ARYLESTERASE; ESTERASE; ISOENZYME; LINOLEIC ACID; LIPID PEROXIDE; PEROXIDASE;

ARTICLE; CAROTID ARTERY DISEASE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; HYDROLYSIS; LIPID PEROXIDATION; PRIORITY JOURNAL;

EID: 0034738140     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.21.2510     Document Type: Article

References (32)

1. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
3. Badimon JJ, Fuster V, Chesebro JH, et al. Coronary atherosclerosis: a multifactorial disease. Circulation. 1993;87(suppl 3):II-3-II-16.
4. Aviram M. Antioxidants in restenosis and atherosclerosis. Curr Int Cardiol Rep. 1999;1:66-78.
5. Yla-Herttuala S, Palinski W, Rosenfeld ME. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
6. Aviram M, Maor I, Keidar S, et al. Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated. Biochem Biophys Res Commun. 1995;216: 501-513.
7. Blatter M-C, James RW, Messmer S, et al. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem. 1993;211:871-879.
8. Don MM, Masters CJ, Winzor DJ. Further evidence for the concept of bovine plasma arylesterase as a lipoprotein. Biochem J. 1975;151: 625-630.
9. Ayub A, Mackness MI, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19:330-335.
10. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin dependent diabetes mellitus. Atherosclerosis. 1991;86:193-199.
11. Mackness B, Hunt R, Durrington PN, et al. Increased immunolocalization of paraoxonase, clusterin and apolipoproteins A-I in the progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:233-1238.
12. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
13. Adkins S, Gan KN, Mody M, et al. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52:598-608.
14. Humbert R, Adler DA, Disteche CK, et al. The molecular basis of human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76.
15. Aviram M. Does paraoxonase play role in susceptibility of cardiovascular disease? Mol Med Today. 1999;5:381-386.
16. Navab M, Berliner JA, Watson AD, et al. The yin and yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol. 1996;16: 831-842.
17. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest. 1998;101: 1581-1590.
18. Mackness MI, Arrol S, Abbott C, et al. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
19. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low-density lipoprotein. J Clin Invest. 1995;96:2882-2891.
20. Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different that required for its arylcsterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol. 1998;18:1617-1625.
21. Aviram M, Rosenblat M, Billecke S. et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26:892-904.
22. Eckerson HW, Romson J, Wyte C, et al. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet. 1983;35:214-227.
23. Gan KN, Smolen A, Eckerson HW, et al. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Dispos. 1991;19:100-106.
24. Gerner B, Waldeck AR, Witting PK, et al. Oxidation of high density lipoprotein, II: evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem. 1998; 273:6088-6095.
25. Sorenson R, Primo-parmo SL, Kuo OL, et al. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci U S A. 1995;92:7187-7191.
26. El-Saadani M, Esterbauer H, El-Sayed M, et al. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res. 1989;30:627-630.
27. Armstrong D, Hiramitsu T, Gutteridge JMC, et al. E. Studies on experimentally induced retinal degeneration, I: effect of lipid peroxides on electroretinographic activity in the albino rabbit. Exp Eye Res. 1982;35:157-171.
28. Belinky PA, Aviram M, Fuhrman B, et al. The antioxidative effects of the isoflavan glabridin on endogenous constituent of LDL during is oxidation. Atherosclerosis. 1998;137:49-61.
29. Mackness MI, Arrol S, Mackness B, et al. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid peroxidation. Lancet. 1997;349:851-852.
30. Mackness B, Durrington PN, Mackness MI. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet. 1999;353:468-469.
31. Aviram M. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis and the antiatherogenicity of antioxidants. Eur J Clin Chem Clin Biochem. 1996;34:599-608.
32. Aviram M, Dorenfel L, Rosenblat M, et al. Pomegranate juice consumption reduces oxidative stress, low density lipoprotein modifications and platelet aggregation: studies in the atherosclerotic apolipoprotein E deficient mice and in human. Am J Clin Nutr. 2000;71:1-15.